Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles

Journal of Neuroscience

Volumn 34, Issue 12, 2014, Pages 4260-4272

  Castillo Carranza, Diana L ^a,b   Sengupta, Urmi ^a,b   Guerrero Muñoz, Marcos J ^a,b   Lasagna Reeves, Cristian A ^a,b   Gerson, Julia E ^a,b   Singh, Gurpreet ^a,b   Mark Estes, D ^a   Barrett, Alan D T ^a   Dineley, Kelly T ^a,b   Jackson, George R ^a,b   Kayed, Rakez ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Alzheimer's disease; Immunotherapy; Tau oligomers; Tauopathies

Indexed keywords

MONOCLONAL ANTIBODY; TAU OLIGOMER MONOCLONAL ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROBLASTOMA; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ROTAROD TEST; TASK PERFORMANCE; TAUOPATHY; WESTERN BLOTTING; Y-MAZE TEST;

ALZHEIMER'S DISEASE; IMMUNOTHERAPY; TAU OLIGOMERS; TAUOPATHIES;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNIZATION, PASSIVE; MICE; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 84896269359     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3192-13.2014     Document Type: Article

References (75)

1. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27: 9115-9129. CrossRef Medline.
2. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103: 26-35. CrossRef Medline.
3. Bae EJ, Lee HJ, Rockenstein E, HoDH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ (2012) Antibody-aided clearance of extracellular alphasynuclein prevents cell-to-cell aggregate transmission. J Neurosci 32: 13454-13469. CrossRef Medline.
4. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8: 663-672. CrossRef Medline.
5. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. NatMed6: 916-919. CrossRef Medline.
6. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27: 3650-3662. CrossRef Medline.
7. Bi M, Ittner A, Ke YD, Götz J, IttnerLM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6: e26860. CrossRef Medline.
8. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC 3rd, Fontaine SN, Breydo L, Zhang B, Li P, Wang L, Cotman C, Paulson HL, Muschol M, Uversky VN, Klengel T, Binder EB, Kayed R, Golde TE, Berchtold N, Dickey CA (2013) Accelerated neurodegeneration through chaperonemediated oligomerization of tau. J Clin Invest 123: 4158-4169. CrossRef Medline.
9. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224: 472-485. CrossRef Medline.
10. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118: 658-667. CrossRef Medline.
11. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF (2007) Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology 68: 1809-1814. CrossRef Medline.
12. Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R (2013a) Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed) 5: 426-438. Medline.
13. Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R (2013b) Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target? ImmunoTargets and Therapy 2014: 19-28.
14. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286: 34457-34467. CrossRef Medline.
15. Chauhan NB (2007) Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 85: 451-463. CrossRef Medline.
16. Chauhan NB, Siegel GJ (2003) Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 74: 142-147. CrossRef Medline.
17. Cowan CM, Quraishe S, Mudher A (2012) What is the pathological significance of tau oligomers? Biochem Soc Trans 40: 693-697. CrossRef Medline.
18. d'Abramo C, Acker CM, Jimenez HT, Davies P (2013) Tau passive immu-notherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 8: e62402. CrossRef Medline.
19. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad SciU S A 98: 8850-8855. CrossRef Medline.
20. Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT (2011) Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol 70: 588-595. CrossRef Medline.
21. Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11: 155-159. CrossRef Medline.
22. Gallyas F (2008) Physicochemical mechanisms of histological silver staining and their utilization for rendering individual silver methods selective and reliable. Biotech Histochem 83: 221-238. CrossRef Medline.
23. Gerson JE, Kayed R (2013) Formation and propagation of tau oligomeric seeds. Front Neurol 4: 93. CrossRef Medline.
24. Golde TE, Das P, Levites Y (2009) Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets 8: 31-49. CrossRef Medline.
25. Gó mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41: 17-24. CrossRef Medline.
26. Gu J, SigurdssonEM (2011) Immunotherapy for tauopathies. J Mol Neurosci 45: 690-695. CrossRef Medline.
27. Guzmán-Martinez L, Farías GA, Maccioni RB (2013) Tau Oligomers as Potential Targets for Alzheimer's Diagnosis and Novel Drugs. Front Neurol 4: 167. Medline.
28. Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP (2007) Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging 28: 1-7. CrossRef Medline.
29. Hawkins BE, Krishnamurthy S, Castillo-Carranza DL, Sengupta U, Prough DS, Jackson GR, DeWitt DS, Kayed R (2013) Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. J Biol Chem 288: 17042-17050. CrossRef Medline.
30. Henkins KM, Sokolow S, Miller CA, Vinters HV, Poon WW, Cornwell LB, Saing T, Gylys KH (2012) Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol 22: 826-833. CrossRef Medline.
31. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D (1999) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 29: 177-185. CrossRef Medline.
32. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Transcellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287: 19440-19451. CrossRef Medline.
33. Krishnamurthy PK, Deng Y, Sigurdsson EM (2011) Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry 2: 59. CrossRef Medline.
34. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49: 10039-10041. CrossRef Medline.
35. Lasagna-Reeves CA, Glabe CG, Kayed R (2011a) Amyloid-{beta} annular protofibrils evade fibrillar fate in Alzheimer's disease brain. J Biol Chem 286: 22122-22130. CrossRef Medline.
36. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R (2011b) Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 8: 659-665. CrossRef Medline.
37. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R (2011c) Tau Oligomers Impair Memory and Induce Synaptic and Mitochondrial Dysfunction in Wild-type Mice. Mol Neurodegener 6: 39. CrossRef Medline.
38. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012a) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J 26: 1946-1959. CrossRef Medline.
39. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R (2012b) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2: 700. CrossRef Medline.
40. Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE (2003) Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 14: 10-18. CrossRef Medline.
41. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE (2006) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 20: 2576-2578. CrossRef Medline.
42. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25: 402-405. CrossRef Medline.
43. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA (2013) Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem 288: 4056-4065. CrossRef Medline.
44. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A (2006) Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 54: 197-201. CrossRef Medline.
45. Margittai M, Langen R (2004) Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci U S A 101: 10278-10283. CrossRef Medline.
46. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857-868. CrossRef Medline.
47. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D (2011) Passive immunization reduces behavioral and neuropathological deficits in an alphasynuclein transgenic model of Lewy body disease. PLoS One 6: e19338. CrossRef Medline.
48. Morgan D (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63. CrossRef Medline.
49. Morgan D, Munireddy S, Alamed J, DeLeon J, Diamond DM, Bickford P, Hutton M, Lewis J, McGowan E, Gordon MN (2008) Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. J Alzheimers Dis 15: 605-614. Medline.
50. Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58: 188-197. CrossRef Medline.
51. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-332. CrossRef Medline.
52. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 286: 23063-23076. CrossRef Medline.
53. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Agedependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29: 10741-10749. CrossRef Medline.
54. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99: 6364-6369. CrossRef Medline.
55. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754. CrossRef Medline.
56. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63: 1459-1467. CrossRef Medline.
57. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, AsheKH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481. CrossRef Medline.
58. Schneider A, Mandelkow E (2008) Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5: 443-457. CrossRef Medline.
59. Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15: 157-168. Medline.
60. Spires-Jones TL, Kopeikina KJ, Koffie RM, de Calignon A, Hyman BT (2011) Are tangles as toxic as they look? J Mol Neurosci 45: 438-444. CrossRef Medline.
61. Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, Laferla FM (2011) Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol 178: 2811-2822. CrossRef Medline.
62. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181: 1426-1435. CrossRef Medline.
63. Terry RD (2000) Do neuronal inclusions kill the cell? J Neural Transm Suppl 59: 91-93. Medline.
64. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, Stewart GR, Shafer LL (2009) Intracerebroventricular amyloidbeta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A 106: 4501-4506. CrossRef Medline.
65. Troquier L, Caillierez R, Burnouf S, Fernandez-Gómez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9: 397-405. CrossRef Medline.
66. Ubhi K, Masliah E (2011) Recent advances in the development of immunotherapies for tauopathies. Exp Neurol 230: 157-161. CrossRef Medline.
67. van de Nes JA, Nafe R, SchloteW (2008) Non-tau based neuronal degeneration in Alzheimer's disease-an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res 1213: 152-165. CrossRef Medline.
68. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23: 3745-3751. Medline.
69. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24: 6144-6151. CrossRef Medline.
70. Winkler DT, Abramowski D, Danner S, Zurini M, Paganetti P, Tolnay M, StaufenbielM (2010) Rapid cerebral amyloid binding by Abeta antibodies infused into beta-amyloid precursor protein transgenic mice. Biol Psychiatry 68: 971-974. CrossRef Medline.
71. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293: 711-714. CrossRef Medline.
72. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M, Kayed R, Zurzolo C, Di Paolo G, Duff KE (2013) Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288: 1856-1870. CrossRef Medline.
73. Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T (2009) Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 29: 11393-11398. CrossRef Medline.
74. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, HoltzmanDM (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80: 402-414. CrossRef Medline.
75. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337-351. CrossRef Medline.